http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-040281-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
filingDate | 2003-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2005-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AR-040281-A2 |
titleOfInvention | PROCESS FOR THE PREPARATION OF COMPOSITIONS OF AN INHIBITOR OF GLUCOGENO FOSFORILASA AND DOSAGE FORM |
abstract | A process for forming a pharmaceutical composition of a glycogen phosphorylase inhibitor compound comprising the steps of (a) forming dispersion, amorphous, solid particles, each of which comprises a slightly soluble drug and a polymer that increases the concentration; where at least a main portion of said drug is amorphous; (b) mixing said dispersion particles, amorphous, solids and matrix material to form a mixture; (c) cooling said molten mixture and forming solid particles, each comprising said dispersion particles, amorphous, solid and said matrix material: The dosage form of these compounds capable of suppressing hepatic glucose production useful for the treatment of diabetes Claim 5: A process for forming a pharmaceutical composition, characterized in that it comprises the steps of: (a) forming a solution comprising a slightly soluble drug, a polymer that increases the concentration and a solvent; (b) spray drying said solution under conditions in which said solution is atomized to form drops whose size varies between 1 to 500 micrometers, said drops solidify to form said solid, amorphous, dispersion particles comprising said drug and said polymer which the concentration increases, and (c) drying said solid, amorphous dispersion particles again in a separate drying apparatus to remove residual solvent. Claim 11: The process of any of claims 4-10, characterized in that it further comprises an additional excipient selected from the group consisting of a surfactant, a water swellable polymer, a water soluble polymer and a hydrophobic solute. |
priorityDate | 2000-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.